Palisade Bio (PALI) Interest Coverage Ratio (2010 - 2026)
Palisade Bio (PALI) reported Interest Coverage Ratio of 10748.0 for Q1 2026, down 365.28% year-over-year from 4051.55 in Q1 2025, and down 115.37% quarter-over-quarter from 4990.5 in Q4 2025.
Palisade Bio (PALI) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has 17 years of Interest Coverage Ratio data on file, last reported at 10748.0 in Q1 2026.
- Interest Coverage Ratio for Q1 2026 came in at 10748.0, down 365.28% year-over-year; the trailing twelve-month figure through Mar 2026 was 2649.4 (down 135.57% YoY), and the FY2025 annual result was 1805.6, down 45.82% from the prior year.
- Interest Coverage Ratio retreated to 10748.0 in Q1 2026 per PALI's latest filing, from 4990.5 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 472.25 in Q3 2023 and troughed at 10748.0 in Q1 2026.
- A 5-year average of 2313.2 and a median of 1242.83 in 2022 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2023: Interest Coverage Ratio tumbled 340348.72% in 2022, then jumped 57.19% in 2023.
- A 5-year view of Interest Coverage Ratio shows it stood at 1282.67 in 2022, then soared by 38.53% to 788.5 in 2023, then slumped by 42.97% to 1127.33 in 2024, then tumbled by 342.68% to 4990.5 in 2025, then tumbled by 115.37% to 10748.0 in 2026.
- Business Quant data shows PALI's Interest Coverage Ratio at 10748.0 in Q1 2026, 4990.5 in Q4 2025, and 584.4 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Palisade Bio | 391.02 Mn | 261.45 Mn | - | -10,748.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10,748.00 |
| Dec 31, 2025 | -4,990.50 |
| Sep 30, 2025 | -584.40 |
| Jun 30, 2025 | -1,421.50 |
| Mar 31, 2025 | -2,310.00 |
| Dec 31, 2024 | -1,127.33 |
| Sep 30, 2024 | -598.83 |
| Jun 30, 2024 | -2,105.50 |
| Mar 31, 2024 | -3,673.00 |
| Dec 31, 2023 | -788.50 |
| Sep 30, 2023 | -472.25 |
| Jun 30, 2023 | -1,203.00 |
| Dec 31, 2022 | -1,282.67 |
| Sep 30, 2022 | -1,103.25 |
| Jun 30, 2022 | -714.40 |
| Mar 31, 2022 | -3,888.00 |
| Dec 31, 2021 | -805.40 |
| Sep 30, 2021 | -116.00 |
| Jun 30, 2021 | -50.16 |
| Mar 31, 2021 | -1.14 |